Gene: OVOS2

144203
-
alpha-2-macroglobulin like 1 pseudogene
pseudo
12p11.21
NC_000012.12
SNP Mapped
AD
0   
NA (AD)  5.467e-1 (ND)   (Frontal_Cortex)
NA (AD)  NA (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7953222chr12:31158141 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)
rs6487980chr12:31157874 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OVOS2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OVOS2 mRNA"27188386
D000395Air Pollutants, Occupational"Air Pollutants, Occupational results in decreased expression of OVOS2 mRNA"19936710
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of OVOS2 mRNA24449571
C006632arsenic trioxidearsenic trioxide results in decreased expression of OVOS2 mRNA26705709
D002104CadmiumCadmium results in increased expression of OVOS2 mRNA24376830
D019327Copper SulfateCopper Sulfate results in decreased expression of OVOS2 mRNA19549813
D002117CalcitriolCalcitriol results in increased expression of OVOS2 mRNA16002434
D018021Lithium ChlorideLithium Chloride results in decreased expression of OVOS2 mRNA23527032
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of OVOS2 mRNA23103053
C496932panobinostatpanobinostat results in decreased expression of OVOS2 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OVOS2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of OVOS2 mRNA26272509
C017947sodium arsenitesodium arsenite results in increased expression of OVOS2 mRNA28595984
C012589trichostatin Atrichostatin A results in decreased expression of OVOS2 mRNA26272509
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of OVOS2 mRNA"26179874
D014635Valproic AcidValproic Acid results in decreased expression of OVOS2 mRNA23179753|2800136
C111237vorinostatvorinostat results in decreased expression of OVOS2 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004867serine-type endopeptidase inhibitor activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0010951negative regulation of endopeptidase activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005615extracellular space-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

There is no Interaction data for this gene.

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal